Search Results

You are looking at 1 - 10 of 19 items for :

  • "Barriers to clinical trials" x
  • Refine by Access: All x
Clear All
Full access

Barriers to Clinical Trial Participation as Perceived by Oncologists and Patients

Neal J. Meropol, Joanne S. Buzaglo, Jennifer Millard, Nevena Damjanov, Suzanne M. Miller, Caroline Ridgway, Eric A. Ross, John D. Sprandio, and Perry Watts

Although clinical trial research is required for the development of improved treatment strategies, very few cancer patients participate in these studies. The purpose of this study was to describe psychosocial barriers to clinical trial participation among oncologists and their cancer patients. A survey was distributed to all medical oncologists in Pennsylvania and a subset of their patients. Relevant background information and assessment of practical and psychosocial barriers to clinical trial participation were assessed. Among 137 oncologists and 170 patients who completed the surveys, 84% of patients were aware of clinical trials, and oncologists and patients generally agreed that clinical trials are important to improving cancer treatment. However, oncologists and patients were more likely to consider clinical trials in advanced or refractory disease. When considering 7 potential barriers to clinical trials, random assignment and fear of receiving a placebo were ranked highly by both patients and oncologists. Patients identified fear of side effects as the greatest barrier to clinical trial participation, whereas oncologists ranked this psychosocial barrier as least important to their patients. Overall, the study found that although oncologists and patients are aware of clinical trials and have favorable attitudes toward them, psychosocial barriers exist for patients that may impact participation in clinical trials. Furthermore, important discrepancies exist between the perceptions of oncologists and those of patients regarding what the psychosocial barriers are. We concluded that characterizing oncologist and patient perceived barriers can help improve communication and decision making about clinical trials, such that participation may be optimized.

Full access

BPI21-005: Barriers and Facilitators for Clinical Trial Enrollment: A Qualitative Study of the Perspectives of Healthcare Providers

Gaurav Kumar, Priyanka Chaudhary, Aiden Quinn, and Dejun Su

Background: Barriers to clinical trial enrollment have been the subject of numerous research; however, the rate of clinical trial participation has not improved significantly over time. Studies often emphasize patient-related barriers, but

Full access

Cancer Clinical Trial Enrollment: OK Doc, but What’s in It for Me?

Henry Soo-Min Park

, studies suggest multilevel barriers to clinical trial accrual, especially for patients who are elderly, adolescent or young adult, female, ethnic/racial minorities, or socioeconomically disadvantaged. 4 Patients may be burdened by the expenses of travel

Full access

Paving the Road to Clinical Trial Participation: Removing Road Blocks and Directing Patients Toward Novel Therapies

Andrea Wang-Gillam and Kristina Williams

trial accrual. 7 Historically, insurance has also been a barrier to clinical trial participation, 8 particularly for patients seeking to enroll on early phase trials. To address this, our institution has designated personnel to assist in the clinical

Full access

Lost in Translation: Participation in Cancer Clinical Trials for Patients With Limited English Proficiency

Joseph M. Unger

those with the most imminent opportunity to participate. Thus, by addressing the barriers to clinical trial access for patients with LEP, we may further advance the ideal of a more demographically and socioeconomically open and inclusive clinical trial

Full access


collaborations with payers, process improvement, removing economic barriers to clinical trials, and defining and measuring the right outcomes. Panelists agreed there is a need for patient education partnerships and access to those resources in order to enhance

Full access

Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic

Lydia T. Madsen, Deborah A. Kuban, Seungtaek Choi, John W. Davis, Jeri Kim, Andrew K. Lee, Delora Domain, Larry Levy, Louis L. Pisters, Curtis A. Pettaway, John F. Ward, Christopher Logothetis, and Karen E. Hoffman

One barrier to clinical trial enrollment is lack of awareness of available clinical trials. A survey of nearly 6000 patients with cancer found that 85% were either unaware or unsure that participation in clinical trials was an option, although 75% of

Full access

Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal

Ronald Chow, Daniel E. Lage, Grant R. Williams, Mina S. Sedrak, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp

. Lichtman SM . Call for changes in clinical trial reporting of older patients with cancer . J Clin Oncol 2012 ; 30 : 893 – 894 . 22331937 10.1200/JCO.2011.41.0696 59. Kemeny MM , Peterson BL , Kornblith AB , Barriers to clinical

Full access

Participation of Patients With Limited English Proficiency in Gynecologic Oncology Clinical Trials

Soledad Jorge, Shatreen Masshoor, Heidi J. Gray, Elizabeth M. Swisher, and Kemi M. Doll

covariates were not available, which is a limitation of this retrospective study. For example, we were not able to collect information regarding patient comorbidities, which are known barriers to clinical trial enrollment. Another limitation was the use of

Full access

Socioeconomic and Clinical Factors Are Key To Uncovering Disparity in Accrual Onto Therapeutic Trials for Breast Cancer

Carolyn E. Behrendt, Arti Hurria, Lusine Tumyan, Joyce C. Niland, and Joanne E. Mortimer

to clinical trial participation by older women with breast cancer . J Clin Oncol 2003 ; 21 : 2268 – 2275 . 10. Simon MS Du W Flaherty L . Factors associated with breast cancer clinical trials participation and enrollment at a large